Terchang ®, the world's first closed triple inhalation aerosol, was commercially launched in China

Recently, Casey China held the commercial launch meeting of Telchang ® Beclofogg inhaled Aerosol and announced that Telchang ®, the world's first closed triple inhaled aerosol, was officially launched in China. Telchang ® Beclofogg inhalation aerosol is currently the only ultra-fine particle closed triple formulation used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to achieve the treatment of small and large airways.

Taicang ® Beclofogg Aerosol was approved for marketing by the State Medical Products Administration in April 2022, and was included in the national medical insurance list that year, which is one of the few innovative drugs approved in the same year to enter the medical insurance list. Cassie Group is an Italian international pharmaceutical group based on research and development, continuously investing in the development and promotion of innovative treatment options in respiratory diseases, rare diseases and specialty treatments.

Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough and sputum), often progressive airflow obstruction. The active ingredients of Tericong ® Beclofogg aerosol are beclomethasone (ICS), formoterol (LABA) and glyconium bromide (LAMA). Since July 2017, Tericong ® Beclofogg aerosol has been approved in 43 countries and regions including European countries, South Korea and Singapore. Among them, a number of randomized controlled trials (RCTS) of Beclofog have been cited by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for seven consecutive years since 2017. Telchang ® Beclofogg inhalation aerosol can directly reach the small and large airways, significantly improve the small airway function, reduce the acute exacerbation rate of COPD, improve the lung function and symptoms of patients, so as to improve the quality of life of patients.

Improve small airway function,

Unlocking the 'silent zone' of COPD

Chronic obstructive pulmonary disease (COPD) is the third leading killer of human being. In China, there are nearly 100 million people over 20 years old with COPD, and COPD has become a chronic disease seriously threatening public health. The pathological manifestations of COPD are small airway stenosis and parenchymal destruction of the lung. Due to the structural changes of the lung, airflow limitation in COPD is largely irreversible, and more than 90% of COPD patients have small airway lesions. These changes include fibrosis of small airways (inner diameter, < 2 mm) and emphysema characterized by alveolar enlargement and destruction of alveolar-walls.

Small airways are the most easily ignored Silent Zone, and small airway lesions are present in the majority of COPD patients. "Chronic airflow limitation, the classic feature of COPD, results from a combination of small-airway disease and parenchymal destruction (emphysema), with the relative contribution of the two varying from person to person," said Alberto Papi, professor and chair of the Department of Respiratory Medicine, University of Ferrara, Italy, and chief of the Department of Respiratory Medicine, University Hospital Santa Ana. As the disease progresses, acute exacerbations of COPD lead to decreased lung function, an increased economic burden, worse health status, an increased risk of hospitalization, and ultimately an increased risk of death,20 ".

In China, small airway dysfunction is significantly associated with age, sex, urbanization, education level, smoking, passive smoking, biofuel use, exposure to high concentrations of PM2.5, history of chronic cough, history of pneumonia or bronchitis in childhood, family history of respiratory diseases, and increased body mass index (BMI).

From 2017, GOLD proposed ultrafine particles (MMAD&lt; 2 μm) with higher peripheral lung (small airway) deposition 3. Telochang ® Beclofogg aerosol is currently the only ultra-fine particle closed triple formulation, drug particle size (mass median aerodynamic size MMAD) less than 2 μm, small peripheral airway/central airway deposition &gt; The ratio of 2:1 was higher than that of the non-ultrafine powder preparation, which effectively reached both large and small airways and unlocked the "silent zone" of small airways in COPD.

Acute exacerbations in patients with COPD are dangerous.

Ultrafine triple formulations significantly reduced risk and burden

Studies have shown that COPD patients in China are at high risk of acute exacerbations and have a heavy burden. 65% of COPD patients experienced acute exacerbations. The number of acute exacerbations per capita was 1.79, and the number of moderate to very severe COPD patients was 2.92. Professor Chen Rongchang, former chairman of the Chinese Society of Respiratory Disease, current leader of the COPD Group and director of Shenzhen Institute of Respiratory Disease, said: "Acute exacerbations of COPD are clinically harmful. Moderate and severe exacerbations lead to deterioration of quality of life and increased risk of death. Acute exacerbations, failure to adhere to long-term standardized treatment, and recurrent exacerbations pose a serious threat to the lives and health of COPD patients."

Acute exacerbations of chronic obstructive pulmonary disease (COPD) seriously affect the quality of life of patients and are the key link to accelerate disease progression and lead to early death. "Data from the three major studies of Beclofog aerosol (TRIVERSYTI, TRILOGY, and TRIBUTE) confirm that in patients with COPD who have had at least one acute exacerbation in the previous year, The use of beclofog aerosol has significant advantages over the other regimens (ICS/LABA and LABA/LAMA) in improving lung function, reducing exacerbation rates, and improving quality of life.

Professor Liu Yi of Shandong Provincial Hospital, who prescribed the first prescription of Telchang ® Beclofogg inhalation aerosol in China, believes: "Small airway lesions are closely related to acute exacerbations and are mutually causal. Copd patients in China generally have insufficient knowledge of the disease. With the increase of age of COPD patients, inhaled drugs should be able to reach both small and large airways, stable delivery, and easy to use. "As a new generation of closed triple formulations with unique ultrafine particles, the introduction of beclofog aerosol will bring new treatment options for COPD patients in China."

In 2019, COPD was the third leading cause of death worldwide, accounting for more than 3 million deaths annually. The mechanistic relationship between patients with COPD and death is still being explored, but triple inhalation therapy has been shown to reduce the case fatality rate in COPD. GOLD 2023 recommends ICS/LABA/LAMA triple therapy for patients at high risk of acute exacerbations, and meta-analysis results show that ICS/LABA/LAMA triple therapy is a better choice than LABA/LAMA for patients with moderate-to-severe COPD with a history of acute exacerbations. A retrospective Spanish analysis shows lower exacerbation rates and health care expenditures with ultrafine ICS devices than with non-ultrafine ICS devices, and ultrafine triple therapy provides greater benefit to physicians and patients.

The lung function of patients with COPD is impaired, which is easy to affect the inhalation ability. The Telchang ® Beclofogg inhalation aerosol uses the MODULITE® ultra-fine slow fog patented technology pMDI pressure quantitative inhalation device to release MMAD&lt. 2 micron ultrafine particles to reduce drug oropharyngeal deposition; Active spray requires low inspiratory flow rate of patients; MODULITE® ultra-fine slow fog patented technology can slow release the aerosol, reduce the speed of the aerosol, last a long time, and improve the hand-mouth coordination problem; Add cosolvent to form a uniform and stable solution, without shaking before use, each thumbpress output dose is stable, easy to suck and use, direct to the size of the airway, to achieve the size of the airway co-treatment.